Galmed Pharmaceuticals Ltd. Interest Expense 2011-2026 | GLMD

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Galmed Pharmaceuticals Ltd.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	-414 K	-1.44 M	-1.92 M	934 K	65 K	35 K	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
934 K	-1.92 M	-456 K

Quarterly Interest Expense Galmed Pharmaceuticals Ltd.

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	290 K	-	-	-	532 K	-	-	-	90 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
532 K	90 K	304 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Aligos Therapeutics ALGS	2.2 M	$ 8.64	8.07 %	$ 85.4 M	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.66	-1.48 %	$ 8.81 B	Australia
I-Mab IMAB	722 K	-	-	$ 866 M	China
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Amphastar Pharmaceuticals AMPH	23 K	$ 21.36	4.86 %	$ 998 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	58 K	$ 1.47	5.0 %	$ 378 M	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 2.92	-	$ 4.81 M	Israel
Aquestive Therapeutics AQST	6.55 M	$ 4.19	2.7 %	$ 448 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 24.12	-0.37 %	$ 3.07 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Celldex Therapeutics CLDX	927 K	$ 32.59	1.09 %	$ 2.16 B	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.47	-1.34 %	$ 391 M	Britain
Cidara Therapeutics CDTX	5.81 M	-	-	$ 1.41 B	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Brainstorm Cell Therapeutics BCLI	-93 K	-	-2.5 %	$ 5.88 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Akari Therapeutics, Plc AKTX	100 K	$ 4.25	8.35 %	$ 286 B	Britain
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Esperion Therapeutics ESPR	3.49 M	$ 2.22	2.3 %	$ 461 M	USA
Baudax Bio BXRX	1.36 M	-	0.59 %	$ 63 K	USA
Cabaletta Bio CABA	2 M	$ 3.2	2.24 %	$ 322 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
CymaBay Therapeutics CBAY	18.9 M	-	-	$ 3.45 B	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA